Diabetes

The regimen did not show signs of significant hypoglycemia and had a low prevalence of edema despite modest weight gain.

A study reveals that lower baseline BMI and early weight loss with liraglutide enhance significant weight loss outcomes in type 2 diabetes patients.

FDA approves oral semaglutide for reducing cardiovascular risks in high-risk type 2 diabetes patients, enhancing treatment options and outcomes.

Orforglipron demonstrates superior glycemic control in phase 3 trials, showing promise as a new treatment for type 2 diabetes.

The immediacy of data from these monitors is essential in educating patients on managing their chronic disease states.

As shortages end, pharmacies that compound GLP-1s face lawsuits, stricter board oversight, and tougher FDA enforcement.

Pharmacists can help patients maintain muscle mass, meet their protein needs, and prevent nutritional deficiencies through evidence-based guidance that supports better overall health.

Further, they found weight lose prior to 75-g oral glucose tolerance test was a preventative factor for both impaired glucose tolerance and diabetes.

Researchers address impacts of the Inflation Reduction Act on the access, cost, and coverage of glucagon-like peptide-1 medications for patients with diabetes.

As GLP-1 popularity, use, and price continues to rise, pharmacy industry stakeholders are attempting to guide pharmacists and patients around the complexities of this drug class.

Investigators examine the effects of combination therapy with metformin combined with sodium-glucose cotransporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors, or thiazolidinediones.

In part 3 of our interview with Rae McMahan, she explores her role at Prescryptive Health and how she’s helping pharmacy stakeholders navigate complex GLP-1 prescription drug benefits.

The model is designed to increase access, utilization, and adherence to insulin by lowering its maximum price.

Through her work as senior vice president of payor solutions at Prescryptive Health, Rae McMahan shares insights into how increased GLP-1 popularity and costs impact pharmacies.

Rae McMahan, senior vice president of payor solutions at Prescryptive Health, discusses GLP-1 access, advertising, and the challenges that often accompany this drug class.

The clinical impact of sodium-glucose cotransporter 2 inhibitors on adults with type 2 diabetes calls for further research on the risk factors of treatment failure and patients’ economic outcomes.

In an exploration of cardiovascular outcomes, health care utilization, and patient costs, researchers compare glucagon-like peptide-1s with alternative noninsulin glucose-lowering therapies.

Among adults with type 1 diabetes, researchers explore how additional autoimmune diseases impacted patients’ physical and mental health burdens.

Among individuals with both diabetes and HIV, researchers determine patients’ adherence to comprehensive diabetes care interventions.

Medtronic’s diabetes management technology reached 2 milestones upon FDA approval, allowing integration of continuous glucose monitoring for patients with type 1 and type 2 diabetes.

Orforglipron shows results in weight loss and diabetes management, offering a new oral treatment option for patients.

With hypertension commonly leading to increased risk of mortality, researchers aimed to understand the hypertensive survival rates of patients with diabetes over a 20-year period.

Using results from the Rx for Change program in Pittsburgh, Pennsylvania, researchers explored an integrative approach to cardiometabolic disease management among Black patients.

However, caution with empagliflozin use should be applied for patients previously taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.

Certified diabetes care and education specialists and clinical pharmacists are essential members of diabetes care teams.